In This Section:

◄
Guidelines
Review articles
►

Cardiomyopathy

Welcome to our featured section on cardiomyopathy – an educational hub, pulling together the latest clinical data, guidelines, congress updates as well as original video content and expert interviews on the management of cardiomyopathies. Some of the content on this hub is CME-accredited and credits will be available when viewed on Radcliffe Medical Education – our dedicated CME portal. Instructions on how to do so are provided with individual videos.

Please click below to view 4 additional broadcasts about changing the Status Quo in PE Treatment:

See more ▼
Close X
Other videos you might like
xxxx

Section Advisor

Prof Carolyn Lam Su Ping

National Heart Centre Singapore, Duke-NUS, University Medical Centre Groningen, The George Institute for Global Health

The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.

Recent Videos

ESC 2020: Commentary on the EXPLORER-HCM Study

Video

ESC 2020: Commentary on the EXPLORER-HCM Study

Giuseppe Galati,

Video Series

AER: LIVE 2019

Watch time: 6h (13 videos)
VT ablation in non-ischaemic cardiomyopathy

Video

VT ablation in non-ischaemic cardiomyopathy

Steve Murray,

Watch time: 24m 58s
Cardiomyopathy in perspective

Video

Cardiomyopathy in perspective

William Bradlow,

Watch time: 26m 2s
ESC 2019: Actin-myosin modulation in cardiomyopathy - Prof Christine E Seidman

Video

ESC 2019: Actin-Myosin Modulation in Cardiomyopathy

Christine E Seidman,

Watch time: 5m 21s
AHA 2018: TRED-HF Trial

Video

AHA 2018: TRED-HF Trial

Brian Halliday,

Clinical publications

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

Teerlink JR, Diaz R, Felker GM, et al. N Engl J Med 2021;384:105–16.

Mavacamten: treatment aspirations in hypertrophic cardiomyopathy

Papadakis M, Basu J, Sharma S. Lancet 2020;396:736–7.

Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction

Rowin EJ, Maron BJ, Carrick RT, et al. J Am Coll Cardiol 2020;75:3033–43.

Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers

Lorenzini M, Norrish G, Field E, et al. J Am Coll Cardiol 2020;76:550–9.

Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy

Ho CY, Mealiffe ME, Bach RG, et al. J Am Coll Cardiol 2020;75:2649–60.

Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry

Neubauer S, Kolm P, Ho CY, et al. J Am Coll Cardiol 2019;74:2333–45.

Detection of hypertrophic cardiomyopathy using a convolutional neural network-enabled electrocardiogram

Ko WY, Siontis KC, Attia ZI, et al. J Am Coll Cardiol 2020;75:722–33.

Guidelines

Clarification of the Australian heart failure guideline recommendation for primary prevention defibrillator implantation in non‐ischaemic cardiomyopathy

Kistler PM, Atherton JJ, Jennings G. Med J Aust 2020;212:509–510.e1.

Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association

Musunuru K, Hershberger RE, Day SM, et al. Circ Genom Precis Med 2020;13:e000067.

Review articles

Theelectrocardiogram in athletes revisited

Katritsis GD, Katritsis DG. Arrhythmia & Electrophysiology Review 2013;2:99–104.